Germline ERBB3 mutation in familial non-small-cell lung carcinoma: Expanding ErbB's role in oncogenesis

McInerney-Leo, Aideen M., Chew, Hui Yi, Inglis, Po Ling, , Joseph, Shannon R., Cooper, Caroline L., Okano, Satomi, Hassall, Tim, , Bowman, Rayleen V., Gattas, Michael, , , Shaw, Janet G., , Yang, Ian A., , Fong, Kwun M., Simpson, Fiona, & (2021) Germline ERBB3 mutation in familial non-small-cell lung carcinoma: Expanding ErbB's role in oncogenesis. Human Molecular Genetics, 30(24), pp. 2393-2401.

[img]
Preview
Published Version (PDF 761kB)
111732301.
Available under License Creative Commons Attribution 4.0.

Open access copy at publisher website

Description

Lung cancer is the commonest cause of cancer deaths worldwide. Although strongly associated with smoking, predisposition to lung cancer is also heritable, with multiple common risk variants identified. Rarely, dominantly inherited non-small-cell lung cancer (NSCLC) has been reported due to somatic mutations in EGFR/ErbB1 and ERBB2. Germline exome sequencing was performed in a multi-generation family with autosomal dominant NSCLC, including an affected child. Tumour samples were also sequenced. Full-length wild-type (wtErbB3) and mutant ERBB3 (mutErbB3) constructs were transfected into HeLa cells. Protein expression, stability, and subcellular localization were assessed, and cellular proliferation, pAkt/Akt and pERK levels determined. A novel germline variant in ERBB3 (c.1946 T > G: p.Iso649Arg), coding for receptor tyrosine-protein kinase erbB-3 (ErbB3), was identified, with appropriate segregation. There was no loss-of-heterozygosity in tumour samples. Both wtErbB3 and mutErbB3 were stably expressed. MutErbB3-transfected cells demonstrated an increased ratio of the 80 kDa form (which enhances proliferation) compared with the full-length (180 kDa) form. MutErbB3 and wtErbB3 had similar punctate cytoplasmic localization pre-and post-epidermal growth factor stimulation; however, epidermal growth factor receptor (EGFR) levels decreased faster post-stimulation in mutErbB3-transfected cells, suggesting more rapid processing of the mutErbB3/EGFR heterodimer. Cellular proliferation was increased in mutErbB3-transfected cells compared with wtErbB3 transfection. MutErbB3-transfected cells also showed decreased pAkt/tAkt ratios and increased pERK/tERK 30 min post-stimulation compared with wtErbB3 transfection, demonstrating altered signalling pathway activation. Cumulatively, these results support this mutation as tumorogenic. This is the first reported family with a germline ERBB3 mutation causing heritable NSCLC, furthering understanding of the ErbB family pathway in oncogenesis.

Impact and interest:

2 citations in Scopus
2 citations in Web of Science®
Search Google Scholar™

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

Full-text downloads:

32 since deposited on 22 Jun 2022
13 in the past twelve months

Full-text downloads displays the total number of times this work’s files (e.g., a PDF) have been downloaded from QUT ePrints as well as the number of downloads in the previous 365 days. The count includes downloads for all files if a work has more than one.

ID Code: 232780
Item Type: Contribution to Journal (Journal Article)
Refereed: Yes
ORCID iD:
Leo, Paul J.orcid.org/0000-0001-8325-4134
Brown, Matthew A.orcid.org/0000-0003-0538-8211
Duncan, Emma L.orcid.org/0000-0002-8143-4403
Additional Information: Funding: Cancer Council Queensland (#1041390); Queensland Head and Neck Cancer Centre, the Princess Alexandra Research Foundation (#2016030 to F.S.); Queensland University of Technology Cancer Programme Publication Award; National Health and Medical Research Council (NHMRC) Early Career Fellowship (ID 1158111 to A.M.L.); NHMRC Senior Principal Research Fellowship (ID 1024879 to M.A.B.); NHMRC Practitioner Fellowship (ID 1019891) to KF Princess Alexandra Research Foundation to S.R.J. and The Prince Charles Hospital Foundation (NR2012-210 to KF).
Measurements or Duration: 9 pages
DOI: 10.1093/hmg/ddab172
ISSN: 0964-6906
Pure ID: 111732301
Divisions: Current > Research Centres > Centre for Genomics and Personalised Health
Current > QUT Faculties and Divisions > Faculty of Health
Current > Schools > School of Biomedical Sciences
Funding:
Copyright Owner: The Author(s) 2021
Copyright Statement: This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au
Deposited On: 22 Jun 2022 04:51
Last Modified: 12 Jul 2024 12:59